Medindia

X

Oncology Biotech Standout MabVax Therapeutics Interviewed on Small Cap Nation

Friday, September 16, 2016 Cancer News J E 4
Advertisement
Company CEO, David Hansen Provides Insight into Company's Growth Plans

SAN DIEGO, Sept. 16, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that Company CEO, David Hansen, was interviewed by Small Cap Nation's Jane King from the NASDAQ Marketsite in Times Square.  Mr. Hansen provided an insightful update on the Company's recent positive events and upcoming near-term significant milestones. The interview in its entirety is available here.

Key elements of Mr. Hansen's interview touched upon:

  • The uplisting of MBVX shares onto the Nasdaq Capital Market and equity research initiation by Laidlaw & Company.
  • The Company's current status of its clinical development pipeline and updates on significant near-term milestones for MVT-5873, MVT-2163, and MVT-1075, and work on its emerging pipeline of new human antibody candidates.
  • Review of the Company's ongoing collaborations and partnering discussions that include Memorial Sloan Kettering Cancer Center, Rockefeller University and Heidelberg Pharma.

Also participating in the interview was Jeffrey Kraws, founder and senior analyst at Crystal Research Associates, who provided a third-party insight into MabVax's progress across its product developments and clinical trials process.

About MabVaxMabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company's proprietary vaccines.  MabVax's HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK.  In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers.  The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer.  MabVax's two lead antibody clinical programs, currently in Phase I clinical trials, utilize HuMab-5B1 as a naked antibody (MVT-5873) and as an immuno-PET imaging agent (MVT-2163).  Additional information is available at www.mabvax.com.

About SMALL CAP NATIONWE EMPOWER COMPANIES TO ENGAGE, EDUCATE, ACQUIRE AND MANAGE INVESTORS.SmallCapNation is a New York based financial media distribution platform, developing and distributing on-demand video content focusing specifically on the small cap sector. 

Small Cap Nation Video SCN offers two core products:  Video New Releases and Corporate Profiles, each accompanied by our highly targeted distribution capabilities.

Key to the effectiveness of the Small Cap Nation program is our unprecedented distribution network for delivering a company's story to an active small cap investor base.

More than 2.1 million unique viewers have seen our programming since the beginning of 2016, on sites such as Fox Business News, Fox News, The Street.com, Business Insider and the Wall Street Journal.

Forward Looking Statements:This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's clinical trials and product development pipeline.  We have no assurance that all of the product development pipeline will be fully developed by the Company.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2015, as amended and supplemented from time to time and the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

For further information: MabVax Investor Relations858-259-9405 x302 

Robert HaagManaging DirectorIRTH CommunicationsMBVX@irthcommunications.com1-866-976-4784

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncology-biotech-standout-mabvax-therapeutics-interviewed-on-small-cap-nation-300329263.html

SOURCE MabVax Therapeutics Holdings, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Penn Dental Medicine Study Finds Nasal Spray Safe ...
S
Novel Accelerator-Based BNCT Suite to be Delivered...